Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus paclitaxel as second-line and maintenance treatment for advanced gastric cancer
ChiCTR1800017225Phase 4Recruiting
- Sponsor
- Jiangxi Cancer Hospital
- Start
- Jun 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib and paclitaxel in gastric cancer (GC), sponsored by Jiangxi Cancer Hospital. Primary endpoints: progression-free survival and adverse events. Started Jun 2018; status: recruiting.
02
Drugs
Rivoceranibpaclitaxel
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR1800017225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017225.